FDA Mixed up [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2012-10-23 18:34 (4630 d 19:40 ago) – Posting: # 9451
Views: 8,970

Dear Detlew!

❝ I must confess that I never understood why the FDA statisticians (they are, really :cool:) recommend the use of SAS Proc GLM or MIXED within their analysis of intra-subject contrasts for the two different designs within the scABE framework.


Agree. Not the slightest (!) idea. :confused:

❝ Since the contrasts (T-R or R1-R2) are analyzed via an model with sequence group as the solely effect (fixed) both SAS procedures will give exactly the same results AFAIK.


Yes.

❝ On the other hand the Proc Mixed code for unscaled ABE in case of the partial replicate crossover doesn't work in all cases as we had discussed here often.


Oh dear.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,686 registered users;
55 visitors (0 registered, 55 guests [including 9 identified bots]).
Forum time: 14:14 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5